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A B S T R A C T
Schizophrenia and suicidal behaviour are sever and complex mental disorders, largely determined by factors of in-
heritance. Both disorders present pathological changes in the catecholamine neurotransmitter system. The study was
conducted on three groups; a group of subjects suffering from schizophrenia, a second compounded by individuals who
attempted suicide and a third group of phenotypically healthy examinees. The blood samples of schizophrenic patients as
of those who attempted suicide were obtained at the Psychiatric Hospital »Sveti Ivan« in Zagreb in the year 2004. Tests
were conducted on the statistic relation between a total of 18 SNPs within three candidate-genes of the dopamine and
adrenergic system (DRD4, SLC6A3 and ADRA2B) and the manifestation of schzophrenia and suicidal behaviour. Cases
were genotyped by use of SNPlex system. Statistically significant differences were determined in the allelic frequency be-
tween the mentioned groups. Findings show a siginficant connection between 4 SNPs (ADRA2B rs749457, SLC6A3
rs464094, DRD4 rs11246226 and rs4331145) and schizophrenia, and 2 SNPs with suicidal attempt (ADRA2B rs1018351 i
SLC6A3 rs403636). In addition, this is the first study that highlights the potential role/effect of polymorphisms in ADRA2B
on the manifestation of schizophrenia, as on suicidal behaviour.
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Introduction
Schizophrenia is a mental disorder whose main char-
acteristics are alteration of thought, perception, speech,
behaviour, emotion, volition and self perception. The
everage life time risk of schizophrenia is 1% of the overall
population, and in the majority of cases it manifests itself
between 20 and 39 years of age. Around 10% of schizo-
phrenia cases commit suicide, most frequently in the starting
period of the disorder¹.
The course of the disorder can be continuous or with
intervals of partial remission and with progressive and
permanent damage of personality. Most cases, around
50–75% report psychological and social consequences
from the chronic course of the disorder, which most fre-
quently appear within the first year up to two years after
the beginning of the disorder. However, in some cases,
the course of the disorder is discontinuous with oscilla-
tions from psychotic relapsis to remission. A complete re-
mission of symptoms is rare and, depending on studies, is
between 7% and 41% of schizophrenic patients. Both,
Classification of Mental and Behavioural Disorders –
Clinical Descriptions and Diagnostic Guidelines (10th edi-
tion) of the World Health Organization (MKB-10)³ and the 4th
edition of the Diagnostic and Statistical Manual for Men-
tal Disorders (DSM-IV), differentiate, in consideration of
clinical characteristics, five major subtypes of schizo-
phrenia.
Mathematical models taken from former studies on
the inheritance of schizophrenia within families have es-
timated that the genetic influence is 80–85%5.
It is estimated that suicide is the cause of 2% of all
deaths (data of the WHO). Statistics show that in Croa-
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tia, the incidence of suicides is 34.6 in men and 11.7 in
women on 100,0006. Suicidal behaviour assumes suicidal
attempt but also the existance of suicidal thoughts. There
is no particular classification of suicidal disorders accord-
ing to the MKB-10 or DSM-IV classification systems.
Over 90% of subjects who have attempted suicide
present some psychiatric disorder. The most common dis-
orders which are related to suicidal behaviour are mood
disorders, anxiety disorder, PTSD, schizophrenia and ad-
diction (alcoholism).
It is estimated that, in suicidal behaviour and suicide,
the genetic component is responsible for 43% while the
environmental components are responsible for 57% of
the cases.
Former studies are not unison, but they indicate chan-
ges in the monoaminie transmission in both disorders.
The aims of this study are: a) to determin and com-
pare the allelic frequency in the examined groups of
schizophrenia cases and subjects who have attemtped
suicide in relation to a control group of phenotipically
healthy subjects; b) to estimate the (un)balance in the re-
lation between the mentioned polyphormisms within
ADRA2B, DRD4 and SLC6A3 genes; and c) on grounds of
the findings, to assume the effect of disorders in neuro-




Cases of the study were divided in three groups; a first
group consisting of schizophrenic patients, a second of
subjects who attemtped suicide and a third group of
phenotypically healthy subjects. The blood samples of
schizophrenic patients as of those who attempted suicide
were obtained at the »Sveti Ivan« Psychiatric Hospital in
Zagreb in the year 2004. Diagnoses of all patients were
coded according to the MKB-10 Classification of Mental
and Behavioural Disorders. The shizophrenia cases did
not attempt suicide and do not have suicidal thoughts
(verified during a structured interview and after objective
psychological questionnaires). The first group consisted
of 103 subjects between 23 and 74 years of age (mean age
43.5±10.55). The subjects classification according to MKB-
-10 types of schizophrenia and the characteristics of the
cases according to sex are presented in Table 1.
The group of subjects who attempted suicide con-
sisted of 125 individuals aged between 19 and 94 years
(mean age 43.6±17.58) who were treated at the »Sveti
Ivan« Psychiatric Hospital during the year 2004 and who
did not suffer from schizophrenia. Diagnostic categories
according to the MKB-10 cassification and according to
sex are presented in Table 2. Considering the heteroge-
neity of the group that comprises a wide range of psychi-
atric disorders, the subjects were classified in major diag-
nostic groups.
The control group of phenotypically healthy individu-
als, who had not received psychiatric treatment, con-
sisted of 131 unrelated subjects, recruited during the
project »Population structure of Croatia – anthropogenic
approach« supported by the Croatian Ministry of Sci-
ence. The subjects were aged between 30 and 74 years
(mean age 50.3±7.51), and were sampled from 9 Croatian
cities (Zagreb, Zadar, Dubrovnik, Pazin, Zabok, Hvar,
Krk, Donji Miholjac and Delnice).
DNA analysis
Cases DNA was isolated from whole blood (7 mL) ei-
ther by the method given by Muller et al.9, or by Nucleon
Genomic DNA Extraction kit (Tepnel Life Sciences PLC)
standard protocols.
The study was conducted on the following genes:
DRD4, SLC6A3 and ADRA2B. Potentially informative
SNPs were selected using SNPbrowser softwer (Applied
Biosystems), which uses databases of 160,000 integrated
SNPs, given by the company itself by use of the TaqMan
SNP Genotyping techology, as well as of over one million
SNPs proved at the International HapMap project (Hap-
Map Consortium 2004).
Examined genes and the chromosomal location, pre-
cise position (bp), reciprocal distance of the chosen SNPs
as well as the changes of the nucleotides are presented in
Table 3.
Cases SNPs were detected using the SNPIex Geno-
typing System (Applied Biosystems). The genotyping sy-
stem is based on the oligonucleotide ligitation assay
(OLA) (Applied Biosystems), followed by multiplexed
PCR (with polymerase chain reaction).
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TABLE 1
CLASSIFICATION OF THE SCHIZOPHRENIA CASES GROUP AC-
CORDING TO MKB-10 CLINICAL TYPES OF SCHIZOPHRENIA
Diagnosis Males Females Total
F20.0 (paranoid schizophrenia) 35 26 61
F20.1 (hebephrenic schizophrenia) 3 0 3
F20.5 (residual schizophrenia) 23 13 36
F20.6 (simple schizophrenia) 0 3 3
Total 61 42 103
TABLE 2
DIAGNOSTIC GROUPS AND CHARACTERISTICS OF SUICIDAL
CASES
Diagnosis Males Females Total
F03–F07 (organic disorders) 4 7 11
F22–F25 (without F20)
(delusional disorders) 8 12 20
F31–F33 (mood disorders) 11 21 32
F43–F42 (anxiety disorders) 8 11 19
F60–F61 (personality disorders) 11 18 29
F10–F19 (addictions) 5 9 14
Total 47 78 125
After the multiplexed PCR, with a specific probe de-
tector (ZipChute), the allelic SNPs were detected by
capillar electrophoresis on Applied Biosystems 3130 DNA
Analyzer. All steps in the genotyping process were per-
formed by producer’s protocol.
Data analysis
The allelic frequency in the examined polymorphic lo-
cus in the case-control groups were determined by count-
ing, while the allelic association with schizophrenic and
suicidal phenotypes was statistically determined by c2-
-test10. Adjustment for multiple testing was performed
by permuting association results 10,000 times in order to
determine the lowest possible significance level. Statis-
tics programme SPSS for Windows v7.5 was used to per-
form the mentioned computation.
The HW balance was verified by Exact SNP test of the
PEDSTATS programme.
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TABLE 3
TAGS, LOCATION AND RECIPRICAL DISTANCE OF THE ANALYSED POLYMORPHISMS
SNP #rs Allele Tag SNP location Reciprocal distance Chromosome Gene
rs3758653 C/T DRD4_1 626399 11 DRD4
rs11246226 A/C DRD4_2 631191 4792 11 DRD4
rs936465 C/G DRD4_3 633568 2377 11 DRD4
rs4331145 A/G DRD4_4 633683 115 11 DRD4
rs40184 A/G SLC6A3_1 1448077 5 SLC6A3
rs11133767 A/G SLC6A3_2 1454580 6503 5 SLC6A3
rs6869645 C/T SLC6A3_3 1457548 2968 5 SLC6A3
rs6347 A/G SLC6A3_4 1464412 6864 5 SLC6A3
rs37022 A/T SLC6A3_5 1468629 4217 5 SLC6A3
rs464049 C/T SLC6A3_6 1476905 8276 5 SLC6A3
rs460000 A/C SLC6A3_7 1485825 8920 5 SLC6A3
rs403636 G/T SLC6A3_8 1491354 5529 5 SLC6A3
rs3756450 C/T SLC6A3_9 1501148 9794 5 SLC6A3
rs10183151 G/T ADRA2B_1 96196660 2 ADRA2B
rs3813662 G/T ADRA2B_2 96201569 4909 2 ADRA2B
rs1168965 C/G ADRA2B_3 96209773 8204 2 ADRA2B
rs749457 C/T ADRA2B_4 96217818 8045 2 ADRA2B
TABLE 4
PROBABILITY OF HW EXPECTATIONS BETWEEN EXAMINED ALLELES AND THEIR FREQUENCY IN THE CASE-CONTROL
POPULATON (SCHIZOPHRENIA)
SNP SNP rs Alleles Location p (HWE) Controlgroup Cases (sch) c
2 psch
ADRA2B_1 rs1018351 G/T 96196660 1 0.18 0.247 2.697 0.101
ADRA2B_2 rs3813662 T/G 96201569 1 0.043 0.015 3.026 0.082
ADRA2B_3 rs1168965 C/G 96209773 0.78 0.207 0.209 0.003 0.957
ADRA2B_4 rs749457 T/C 96217818 0.802 0.49 0.337 9.867 0.002
SLC6A3_1 rs40184 G/A 1448077 0.009 0.452 0.39 1.138 0.286
SLC6A3_2 rs11133767 A/G 1454580 0.149 0.239 0.196 0.787 0.375
SLC6A3_3 rs6869645 C/T 1457548 0.643 0.098 0.064 1.283 0.257
SLC6A3_4 rs37022 A/T 1468629 0.532 0.25 0.275 0.244 0.622
SLC6A3_5 rs464049 C/T 1476905 0.725 0.355 0.465 4.015 0.045
SLC6A3_6 rs460000 A/C 1485825 0.112 0.283 0.256 0.169 0.681
SLC6A3_7 rs403636 G/T 1491354 1 0.05 0.018 2.547 0.111
SLC6A3_8 rs3756450 C/T 1501148 0.969 0.212 0.195 0.151 0.698
DRD4_1 rs3758653 C/T 626399 0.019 0.395 0.450 0.421 0.517
DRD4_2 rs11246226 A/C 631191 0.736 0.183 0.078 6.100 0.014
DRD4_3 rs936465 C/G 633568 0.417 0.395 0.352 0.267 0.606
DRD4_4 rs4331145 A/G 633683 0.039 0.327 0.202 4.298 0.038
By using the data of the genotype it was possible to
determine the belonging of each individual to one poten-
tial subpopulation, and consequently to possible population
substructures. Cases were tested on a value of K=2.3 and
4, using the linkage model, which assumes a mixed popu-
lation, and a sensitive model of correlated allelic frequen-
cies. Possible substructures of population were tested in
the described fashion by the STRUCTURE programme12.
Results
The data on the examined polymorphisms are pre-
sented in the tables that follow. Table 4 shows the results
of the analysis on the relation between polymorphysims
in ADRA2B, SLC6A3 and DRD4 and the manifestation of
schizophrenia in relation to the control group, while Table
5 refers to examined polymorphisms in suicidal subjects.
Results show a significant allelic association between
4 SNPs and schizophrenia and between 2 SNPs and sui-
cidal attempt. The allele in rs749457 SNP in ADRA2B
shows a strong relation (p<0.01) with suicidal attempt.
Schizophrenia has relation with (p<0.01) both SNPs in
SLC6A3 (rs464094) and in DRD4 (rs11246226, rs4331145),
while suicidal attempt is related with the SNP of the
SLC6A3 gene (rs403636).
D values are used to define haplotype (LD) blocks by
HaploView programme. No significant unbalance in exami-
ned polymorphisms was detected in DRD4. In ADRA2B
there are significant unbalances between the SNPs 2 and
3 (2 kB block) and between 7 ad 8 (5 kB block), but none
of the examined poymorphisms shows a connection with
the manifestation of the disorder.
Discussion and Conclusions
The inheritance component plays a very significant
role in etiopathogenesis of schizophrenia and suicidal be-
haviour. We assume that a better knowledge of the patho-
physiological mechanisms of schizophrenia and suicidal
behaviour, along with the discovery of the genes respon-
sible for their development, may enable early diagnosis
and better treatment13. The structure of the Croatian
population, in particular that of its islands, has been
studied for several years and started as part of anthropo-
logical projects back in 1971 by Rudan et al.14.
Disorders of the mesolimbic dopamine pathway may
lead to the manifestation of a positive group of psycho-
pathological symptoms of schizophrenia, while the re-
duced activity of mesocortical dopamine pathway causes
negative symptoms and cognitive disorders15. Noradre-
naline, through its receptors, can affect the variability
and reactivity of dopamine neurons.
Subjects who attempted suicide present a reduced
level of noradrenaline in the limbic regions of the brain,
but a higher level in the PFC (prefrontal cortex). In addi-
tion, there is evidence of reduced dopamine transmis-
sion.
This study focuses on two genes of the dopamine sys-
tem, DRD4 and SLC6A3, and the gene of the noradre-
nergic system ADRA2B. According to available data,
there are no associative studies on these genes on the
Croatian population (search of Croatian Scientific Liter-
ature).
The SLC6A3 gene codes for the dopanime pathway
which transfers dopamine from the extracellular area
into the neuron. An extensive study conducted by Tal-
kowski et al.16 showed the relation between 3 SNPs of
SLC6A3 gene, among which is rs46409 and schizophre-
nia, and that matches with our results. The frequency of
a rare allele in SPN rs46409 (f=0.48) in patients is com-
parable to the frequency of the same allele in the part of the
Croatian population affected by schizophrenia (f=0.465).
This SNP is situated in the third intron of SLC6A3,
therefore we can assume its possible influence on the ex-
pression of the functional proteine.
A change of expression of the transporter may cause
an increased quantity of dopamine, and may consequen-
tly increase the effects of dopamine transmission. The
expression of SLC6A3 is highest in the striatum, and is
almost absent in PFC17. A non-functional dopamine trans-
porter could lead to a hyperactivity of the dopamine sys-
tem in the subcortical regions of the brain and, at the
same time, due to the regulation of the feedback, it could
cause the reduction of the activity of the dopamine sys-
tem in PFC17.
We assume that the dopamine pathway is reduced in
suicidal subjects. Hypothetical changes in the function-
ing of the dopamine transporter connected with SNP
rs403636 could contribute to the deficits of the dopamine
system in subjects who attempted suicide. Considering
that there exists a mutual regulation of the serotonin
and dopamine systems, a reduced serotonin transmission
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TABLE 5
ANALYSIS OF THE RELATION OF THE POLYMORPHISMS IN






ADRA2B_1 0.18 0.286 0.009 0.009
ADRA2B_2 0.043 0.024 0.249 0.249
ADRA2B_3 0.207 0.268 0.158 0.158
ADRA2B_4 0.49 0.476 0.758 0.758
SLC6A3_1 0.452 0.643 3.042 0.081
SLC6A3_2 0.239 0.825 1.971 0.160
SLC6A3_3 0.098 0.111 0.182 0.670
SLC6A3_4 0.25 0.297 0.919 0.338
SLC6A3_5 0.355 0.402 0.805 0.370
SLC6A3_6 0.283 0.815 2.663 0.103
SLC6A3_7 0.05 0.986 4.152 0.042
SLC6A3_8 0.212 0.292 2.962 0.085
DRD4_1 0.395 0.430 0.115 0.896
DRD4_2 0.183 0.104 3.236 0.072
DRD4_3 0.395 0.284 2.195 0.138
DRD4_4 0.327 0.242 2.117 0.145
could be the cause of changes in the transmission of
dopamine18.
A high number of genetic studies indicate influence of
polymorphysms in DRD4 on the schizophrenic pheno-
type. A meta-analysis (SzGene database) shows a higher
incidence of S alleles 120pb ins/del polymorphisms in
DRD4 in subjects suffering from schizophrenia (OR (95%
CI)=0.81 (0.7, 0.94)). Studies on the relation between
40pb VNTR polymorphisms and schizophrenia are mainly
negative as regards the Caucasion population. Talkowski
et al.16 did not find any connection between the SNPs of
the DRD4 gene and schizophrenia. However, the results
of this study indicate a connection betwen the alleles of
two SNPs (rs11246226, rs4331145) in the 3rd region of
the DRD4 gene and schizophrenia.
This study shows that there exists a connection be-
tween SNPs in ADRA2B and schizophrenia and suicidal
attempt. The SNP rs749457 is situated in the 3rd region
of the ADRA2B gene and is connected with schizophre-
nia, while rs10181251 is situated in the 5th region of the
gene and is connected with suicidal attempt.
According to our knowledge, this is the first study
that points out a potential role of polymorphisms within
a region of the ADRA2B gene in the manifestation of psy-
chiatric disorders.
Evidence of the importance of the ADRA2 receptors
in schizophrenia is the efficiency of clozapine, which is
also the antagonist of the ADRA2 receptors. Clozapine
reduces suicidal behaviour regardless of its antipsychotic
effect19, as the ADRA2 receptors can modulate the trans-
mission of serotonin. We can assume that polymorphisms
alone or the neighbouring genetic regions related to the
examined SNPs are functional in relation to a more in-
tense activity of ADRA2B receptors. An intense activity
of the examined receptor would increase the risk of a
manifestation of schizophrenia and/or suicidal attempt.
The antagonists of ADRA2 receptors also reduce the
variability of dopamine transmission in the ventral teg-
mental area (VTA). Besides the influence on the me-
solimbic system, the antagonists of ADRA2 also increase
the availability of dopamine in PFC, hence milding cogni-
tive disfunction20.
Yamamoto et al.21 suggested a theory according to
which positive symptoms of schizophrenia would be the
consequence of hyperactivity of the noradrenergic sys-
tem, while negative symptoms a consequence of its hypo-
activity22.
At the origin of impulsivity lies a reduced serotonin
transmission, while the cause of feelings of helplessness
is a reduced noradrenergic transmission. Both phenom-
ena may eventually lead a subject to suicidal attempt23.
In conclusion, the results of the study have hypotheti-
cal biological grounds in the pathological changes of
catecholamine systems in schizophrenia and suicidal be-
haviour24. Further studies on the subject are needed in
order to determin a possible significance of the examined
SNPs in SLC6A3, DRD4 and ADRA2B in the functional-
ity of their protein products25.
A limitation of this study lies in the small sample.
Positive results give way to future studies which would
be conducted on a much wider range of subjects of Cro-
atian origin and their detailed stratification
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POREDBENO ISTRA@IVANJE GENSKIH BILJEGA NEUROTRANSMITORSKIH SUSTAVA U
SHIZOFRENIH I SUICIDALNIH OSOBA
S A @ E T A K
Shizofrenija i suicidalno pona{anje su te{ki i kompleksni te velikim dijelom nasljednim faktorima determinirani
psihi~ki poreme}aji. U oba poreme}aja postoje patolo{ke promjene u katekolaminergi~kim neurotransmitorskim sus-
tavima. U istra`ivanje su bile uklju~ene tri skupine ispitanika; skupina oboljelih od shizofrenije, skupina osoba koje su
poku{ale samoubojstvo i skupina fenotipski zdravih ispitanika. Uzorci krvi shizofrenih bolesnika kao i osoba koje su
poku{ale samoubojstvo prikupljeni su u Psihijatrijskoj bolnici »Sveti Ivan« u Zagrebu tijekom 2004. godine. Ispitana je
statisti~ka povezanost ukupno 18 SNP-ova unutar tri gena dopaminskog odnosno adrenergi~kog sustava (DRD4, SLC6A3
i ADRA2B) s pojavom shizofrenije odnosno suicidalnog pona{anja. Ispitanici su genotipizirani kori{tenjem SNPlex sus-
tava obzirom na navedenih 18 polimorfizama. Utvr|ene su statisti~ki zna~ajne razlike u u~estalosti ispitivanih alela
izme|u navedenih skupina. Rezultati pokazuju zna~ajnu povezanost 4 SNP-a (ADRA2B rs749457, SLC6A3 rs464094 te
DRD4 rs11246226 i rs4331145) sa shizofrenijom i 2 SNP-a s poku{ajem samoubojstva (ADRA2B rs1018351 i SLC6A3
rs403636). Uz to, ovo istra`ivanje je prvo koje ukazuje na potencijalnu ulogu/u~inak polimorfizama unutar ADRA2B
gena u nastanku shizofrenije, kao i u podlozi suicidalnog pona{anja.
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